Chronic kidney disease in patients with diabetes mellitus: new challenges

Chronic kidney disease (CKD) is a supranosological concept, defined as a disorder of the structure and/or function of the kidneys for 3 months or more that leads to health consequences. CKD develops in 20–40% of patients with diabetes mellitus (DM). Dynamic analysis of epidemiological indicators of CKD in patients with diabetes mellitus points to the prevalence increase of this pathology in the Russian Federation in 2010–2022. Improved quality of diagnostics of earlier stages complications, a decrease in the risk of cardiovascular events (the leading cause of death) and end-stage renal failure at a later age and with a longer duration of diabetes are noted as well. The development of tools for predicting the risk of the pathology progression and its complications has made it possible to improve patient monitoring and routing. Current international and domestic recommendations emphasize a comprehensive approach to the treatment of CKD, including lifestyle modification, evidence-based pharmacological treatments aimed at preserving organ function, and improving cardiovascular prognosis. An optimal model of care for patients with diabetes and CKD, aimed at multidisciplinary care and adapted according to the severity of CKD, will lead to the best outcomes for the individual patient and society.

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi: https://doi.org/10.1016/j.kint.2023.10.018

2. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11. doi: https://doi.org/10.1016/j.kisu.2021.11.003

3. United States Renal Data System, USRDS 2022 Annual Data Report [Internet]. U.S. Department of Health and Human Services [cited 2023 Sep 23]. Available from: https://usrds-adr.niddk.nih.gov/2022

4. de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-3090. doi: https://doi.org/10.1016/j.kint.2022.08.012

5. Melena I, Piani F, Tommerdahl KL, et al. Aminoaciduria and metabolic dysregulation during diabetic ketoacidosis: Results from the diabetic kidney alarm (DKA) study. J Diabetes Complications. 2022;36(6):108203. doi: https://doi.org/10.1016/j.jdiacomp.2022.108203

6. Shamkhalova MS, Vikulova OK, Zheleznyakova AV, et al. Trends in the epidemiology of chronic kidney disease in patients with diabetes in Russian Federation according to the Federal register (2010–2022). Diabetes mellitus. 2023;26(5):404-417. (In Russ.)] doi: https://doi.org/10.14341/DM13090

7. Dedov II, Shestakova MV, Vikulova OK et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104-123. (In Russ.)]. doi: https://doi.org/10.14341/DM13035

8. KDIGO 2012 Clinical practice guideline for the evaluations and management of chronic kidney disease. Kidney Int Suppl. 2012;3(1):S1-S150. doi: https://doi.org/10.1038/kisup.2012.73

9. Vikulova OK, Elfimova AR, Zheleznyakova AV, et al. Chronic kidney disease risk calculator: new possibilities for predicting pathology in patients with diabetes mellitus. Consilium Medicum. 2022;24(4):224–233. (In Russ.)]. doi: https://doi.org/10.26442/20751753.2022.4.201684

10. Rossiiskaya assotsiatsiya endokrinologov. Klinicheskie rekomendatsii «Sakharnyi diabet 1 tipa u vzroslykh», 2022. (In Russ.)] Available from: https://cr.minzdrav.gov.ru/preview-cr/286_2

11. Rossiiskaya assotsiatsiya endokrinologov. Klinicheskie rekomendatsii «Sakharnyi diabet 2 tipa u vzroslykh», 2022. (In Russ.)] Available from: https://cr.minzdrav.gov.ru/preview-cr/290_2

12. Mcguire DK, Shih WJ, Cosentino F et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. A meta-analysis. JAMA Cardiology. 2021;6(2):148-158. doi: https://doi.org/10.1001/jamacardio.2020.4511

13. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi: https://doi.org/10.1056/NEJMoa1811744

14. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446. doi: https://doi.org/10.1056/NEJMoa2024816

15. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127. doi: https://doi.org/10.1056/NEJMoa2204233

16. Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-785. doi: https://doi.org/10.1016/S2213-8587(19)30249-9

17. Perkovic V, Tuttle KR, Rossing P, et al. FLOW Trial Committees and Investigators Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. doi: https://doi.org/10.1056/NEJMoa2403347

18. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229. doi: https://doi.org/10.1056/NEJMoa2025845

19. Yevloyeva MI, Arutyunova MS, Severina AS, et al. Chronic kidney disease in patients with long-term type 1 diabetes mellitus. Diabetes mellitus. 2023;26(6):504-514. (In Russ.)] doi: https://doi.org/10.14341/DM13108

20. Heerspink HJL, Birkenfeld AL, Cherney DZI, et al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract. 2023;204:110908. doi: https://doi.org/10.1016/j.diabres.2023.110908

21. Andrusev AM, Peregudova NG, Shinkarev MB, Tomilina NA. Kidney replacement therapy for end Stage Kidney disease in Russian Federation, 2016-2020 Russian National Kidney Replacement Therapy. Registry Report of Russian Public Organization of Nephrologists “Russian Dialysis Society”. Nephrology and Dialysis. 2022;24(4):555-565. (In Russ.)] doi: https://doi.org/10.28996/2618-9801-2022-4-555-565

22. Gautier SV, Khomyakov SM. Organ donation and transplantation in the Russian Federation in 2021. 14th Report from the Registry of the Russian Transplant Society. Russian Journal of Transplantology and Artificial Organs. 2022;24(3):8-31. (In Russ.)] doi: https://doi.org/10.15825/1995-1191-2024-3-8-31

23. Bikbov BT, Tomilina NA. Renal Replacement Therapy for ESRD patients with CAPD and kidney transplantation in Russian Federation, 1998-2011. Report of Russian RRT Registry, Part 2. Nephrology and Dialysis. 2014;16(2):192-227. (In Russ.)]

24. Young BY, Gill J, Huang E, et al. Living donor kidney versus simultaneous pancreas-kidney transplant in type I diabetics: an analysis of the OPTN/UNOS database. Clin J Am Soc Nephrol. 2009;4(4):845-852. doi: https://doi.org/10.2215/CJN.02250508

25. Glazunova AM. Dinamika metabolicheskikh, gormonal’nykh i gemodinamicheskikh faktorov u bol’nykh sakharnym diabetom 1 tipa posle transplantatsii pochki i sochetannoi transplantatsii podzheludochnoi zhelezy i pochki. [dissertation] Moscow; 2016. (In Russ.)]

26. Dmitriev IV, Severina AS, Zhuravel NS, et al. Continuous Glucose Monitoring in Patients Following Simultaneous Pancreas-Kidney Transplantation: Time in Range and Glucose Variability. Diagnostics (Basel). 2023;13(9):1606. doi: https://doi.org/10.3390/diagnostics13091606